Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Up to $2.24

Posted by Defense World Staff on Apr 23rd, 2023

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating)’s share price gapped up prior to trading on Friday . The stock had previously closed at $2.24, but opened at $2.29. Lyell Immunopharma shares last traded at $2.26, with a volume of 82,883 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on LYEL. HC Wainwright dropped their target price on Lyell Immunopharma from $11.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, March 2nd. Morgan Stanley dropped their target price on Lyell Immunopharma from $7.00 to $4.00 and set an “equal weight” rating for the company in a report on Tuesday, January 24th.

Lyell Immunopharma Stock Performance

The stock has a fifty day moving average of $2.34 and a 200-day moving average of $3.62. The company has a market cap of $576.60 million, a PE ratio of -3.12 and a beta of -1.55.

Lyell Immunopharma (NASDAQ:LYEL – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.28. Lyell Immunopharma had a negative return on equity of 21.53% and a negative net margin of 216.24%. The company had revenue of $48.39 million during the quarter, compared to analysts’ expectations of $2.85 million. As a group, equities analysts anticipate that Lyell Immunopharma, Inc. will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Mariner LLC bought a new stake in Lyell Immunopharma during the 4th quarter valued at $35,000. E Fund Management Co. Ltd. raised its position in Lyell Immunopharma by 112.6% during the 4th quarter. E Fund Management Co. Ltd. now owns 30,177 shares of the company’s stock valued at $105,000 after purchasing an additional 15,986 shares in the last quarter. Vident Investment Advisory LLC raised its position in Lyell Immunopharma by 68.4% during the 4th quarter. Vident Investment Advisory LLC now owns 222,691 shares of the company’s stock valued at $773,000 after purchasing an additional 90,435 shares in the last quarter. Alpine Global Management LLC bought a new stake in Lyell Immunopharma during the 4th quarter valued at $94,000. Finally, Two Sigma Investments LP bought a new stake in Lyell Immunopharma during the 4th quarter valued at $570,000. 45.04% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

(Get Rating)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.